Expected Moves

Expected announcement for GWIN's Q2 2026 financials, with intense focus on runway and capital structure given zero reported historical revenues.

High probability of equity issuance or convertible debt offering to fund ongoing operations, as negative net income persists with zero operating cash flow.

Q3 2026 expected results, testing management's ability to demonstrate progression in its biotech pipeline rather than just administrative cash burn.

Expected early-year clinical or pre-clinical pipeline update, customary for the biotech sector around Q1 industry conferences.

Full-year 2026 financials and going-concern evaluation by auditors.

First quarter 2027 results, serving as a critical juncture for GWIN to either secure terminal value or face total capital depletion.